Benjamin Tjoa, Chief Scientist
Benjamin Tjoa received his Ph.D. in Biochemistry/Immunology from the University of Illinois at Urbana-Champaign. With over 20 years of experience, Dr. Tjoa has held various positions in R&D, product development, and translational research.
As a Senior Scientists at Northwest Biotherapeutics, Dr. Tjoa studied human dendritic cell basic biology, in vitro generation, antigen-loading, maturation, pre-clinical dendritic cell-based cancer vaccine studies, and assay developments. He published over 20 scientific articles and earned two patents.
Before joining Astarte Biologics, Dr. Tjoa also held VP of R&D and Lead Scientist positions at Sangretech Biomedical and Bostwick Therapeutics where he led research teams in the development of “second generation” dendritic cell-based vaccines for solid tumors and conducted process development and qualification for a GMP production of a cellular cancer vaccine for clinical testing.
As one of the first scientists to develop dendritic cells for use in cell-based vaccines, Dr. Tjoa has traveled internationally to set up laboratories for dendritic cell-based therapies.
Murphy G.P.; Boynton A.L.; Tjoa B.A. Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy. Application Number US5788963. Filed July 31, 1995.
Tjoa B.A.; Bosch M.L. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines. Application Number: US8389278. Filed February 27, 2004.
Generation and analysis of human T cell lines responsive to Glatiramer Acetate. American Academy of Neurology. 2018.
Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. Journal of Urology. 2004.
Development of dendritic-cell based prostate cancer vaccine. Immunology Letters. 2000.
Progress in active specific immunotherapy of prostate cancer. Seminars in Surgical Oncology. 2000.
Dendritic cell-based immunotherapy for prostate cancer. CA: A Cancer Journal for Clinicians. 1999.
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate. 1999.
Dendritic cell-based immunotherapy of prostate cancer. Critical Reviews in Immunology. 1998.
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate. 1998.
Diversity of T cell receptor-alpha chain transcripts from hyperimmune alloreactive T cells. Journal of Immunology. 1992.
Sequence diversity of T cell receptor alpha chain transcripts from BALB/c thymus. Molecular Immunology. 1992.